Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study
Journal
Journal of clinical medicine
Journal Volume
11
Journal Issue
20
Date Issued
2022-10-21
Author(s)
Yang, Chin-Yi
Lai, Po-Ju
Chen, Chun-Bing
Chan, Tom C
Hui, Rosaline Chung-Yee
Huang, Yu-Huei
Tseng, Han-Chi
Lin, Shang-Hung
Lu, Chun-Wei
Lee, Hua-En
Lin, Jing-Yi
Chi, Min-Hui
Tsai, Ming-Feng
Hwang, Yih-Shiou
Wang, Chuang-Wei
Chung, Wen-Hung
Abstract
To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18-87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator's Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month 12, while prurigo and lichenoid phenotypes were associated with a lower proportion of EASI-75 at month 12. However, the majority of adverse events were mild in severity. In conclusion, our study results identify phenotype-related dupilumab response at month 12 in adults with moderate-to-severe AD, and we suggest that treatment should not be discontinued until reaching a satisfactory clinical response.
Subjects
atopic dermatitis
biomarker
dupilumab
eczema phenotype
efficacy
Type
journal article